<p> 2018 年 4 月 7 日</p><p>Alliance for Clinical Trials in Oncology November 8, 2013 Intercontinental Chicago O’Hare Rosemont, IL Room TBD, 11:30am-2:30pm</p><p>Respiratory Committee</p><p>Chair: Everett E. Vokes, M.D. Vice-Chairs: Dennis Wigle (Surgery) Steven Schild (Radiation Oncology) Pasi Janne (Correlative Science) Jeff Crawford (CALGB) Alex Adjei (NCCTG)</p><p>1. Committee overview and protocol accrual–Everett Vokes and Xiaofei Wang</p><p> Educational Updates: New since ASCO:</p><p> o WCLC-TBA</p><p> o ECCO- Update on vaccine trials – Beppe Giacone</p><p>2. Early Stage Non-Small Cell Lung Cancer and Surgical Studies- Dennis Wigle</p><p> CALGB 140503: Lobectomy vs. limited resection – Nasser Altorki</p><p> E 1505: Intergroup adjuvant bevacizumab study – Stephen Graziano</p><p> Z41102- ALCHEMIST Personalized Adjuvant Therapy in Patients with </p><p>Completely Resected Non-Small Cell Lung Cancer –Geoffrey Oxnard, Pasi </p><p>Janne, Dennis Wigle, Ramaswamy Govindan</p><p>3. Stage III Non-Small Cell Lung Cancer-Steven Schild</p><p> RTOG 1306: Personalized therapy for inoperable stage III NSCLC - Olwen </p><p>Hahn, Ramaswamy Govindan</p><p> CALGB 31102: Hypofractionated XRT for stage III NSCLC - James Urbanic</p><p>4. Stage IV Non-Small Cell Lung Cancer 2018 年 4 月 7 日</p><p> CALGB 30607: Sunitinib as maintenance therapy – Mark Socinski, Maria </p><p>Baggstrom</p><p> CALGB 30801: Cox-2 inhibition in stage IV NSCLC – Martin Edelman</p><p> SWOG 0819: Chemo-(bev) +/- cetuximab – Lyudmila Bazhenova</p><p> CALGB 31002/ACCRUE: Erlotinib +/- bevacizumab for NSCLC patients with </p><p>EGFR mutation – Tom Stinchcombe</p><p> E2512: A phase I/randomized phase II study of docetaxel with or without </p><p>AZD4547 in recurrent FGFR1-amplified squamous NSCLC. – Victoria Villaflor</p><p> Rare genotypes trial– Geoffrey Oxnard, Pasi Janne</p><p> Selumetinib – Bryan Schneider, Pasi Janne</p><p> 2nd line studies in NSCLC-Martin Edelman and subcommittee</p><p> SWOG Squamous Master Protocol</p><p>5. Small Cell Lung Cancer</p><p> CALGB 30610: Limited Stage Intergroup Trial– Jeffrey Bogart and Greg </p><p>Masters</p><p> RTOG 0937 – Steve Schild</p><p> Update on Sunitinib, nintendanib– Neal Ready, Jeff Crawford and </p><p> subcommittee</p><p> Update on RTOG 0617- Jeffrey Bogart</p><p>6. Mesothelioma–Robert Kratzke, Hedy Kindler</p><p> CALGB 30901 - Pemetrexed maintenance Study – Arkadiusz Dudek</p><p>7. Correlative Science-Pasi Janne</p><p> Imaging modeling project – Michael Maitland</p><p> Overview of current projects –Robert Kratzke, Stephen Graziano, Pasi </p><p>Janne 2018 年 4 月 7 日</p><p>8. Patient version of CTCAE being developed by NCI – Ethan Basch and Diana </p><p>Mehedint</p>